Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis.

Author: ChenShuqing, CuiYimin, MaLingyue, MuGuangyan, XiangQian, XieQiufen, ZhangZhuo, ZhouShuang

Paper Details 
Original Abstract of the Article :
OBJECTIVE: The purpose of this systematic review and meta-analysis was to summarize the potential impact of CYP2C8 and SLCO1B1 genetic polymorphisms on repaglinide pharmacokinetics. METHODS: A systematic search was conducted using electronic databases. Eligible studies reported data from pharmacoki...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.2174/1389200220666190111114146

データ提供:米国国立医学図書館(NLM)

Genetic Polymorphisms and Repaglinide Pharmacokinetics

Repaglinide is a medication used to manage type 2 diabetes by stimulating insulin production. This research explores the impact of genetic variations in two specific genes, CYP2C8 and SLCO1B1, on the pharmacokinetics of repaglinide. The study aims to determine if these genetic variations influence how the body metabolizes and eliminates repaglinide, potentially leading to variations in drug effectiveness.

Genetic Influence on Repaglinide Metabolism

The study reveals that genetic variations in CYP2C8 can influence the pharmacokinetics of repaglinide, while variations in SLCO1B1 do not appear to have a significant impact. The researchers found that individuals with certain CYP2C8 genotypes experience lower levels of repaglinide in their blood, suggesting potential variations in drug efficacy. This finding underscores the need for personalized medicine approaches that consider individual genetic profiles to optimize treatment outcomes.

Personalized Medicine in Diabetes Management

This research highlights the growing importance of personalized medicine in managing chronic conditions like diabetes. Understanding the influence of genetic variations on drug metabolism can help healthcare providers tailor treatment plans to individual needs, potentially leading to more effective and safer outcomes for patients. The study emphasizes the need for further research to investigate the role of genetic testing in diabetes management and to develop personalized treatment strategies based on individual genetic profiles.

Dr.Camel's Conclusion

Like the intricate patterns of sand dunes, genetic variations can have a profound impact on how our bodies respond to medications. This study sheds light on the importance of personalized medicine in diabetes management, reminding us that a one-size-fits-all approach may not always be the most effective. Future research in this area can help us navigate the ever-changing landscape of personalized medicine and create more tailored treatment strategies for individuals with diabetes.

Date :
  1. Date Completed 2019-11-27
  2. Date Revised 2019-11-27
Further Info :

Pubmed ID

30636597

DOI: Digital Object Identifier

10.2174/1389200220666190111114146

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.